{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:01:14Z","timestamp":1780992074293,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:27:56Z","timestamp":1764635276000},"page":"e385-e396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent COVID-19 in Patients With Hematological Malignancies: A Focused Review in the Omicron Era"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-7737","authenticated-orcid":false,"given":"Hajime","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106432","article-title":"Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study","volume":"90","author":"Quint","year":"2025","journal-title":"J Infect"},{"issue":"731","key":"10.1016\/j.clml.2025.11.009_bib0002","doi-asserted-by":"crossref","first-page":"eadk1599","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0003","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","article-title":"Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections","volume":"15","author":"Nooruzzaman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.11.009_bib0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2022.01.011","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: threat for the elderly?","volume":"158","author":"Chavda","year":"2022","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.clml.2025.11.009_bib0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cancers16020379","article-title":"COVID-19 outcomes in patients with hematologic malignancies in the era of COVID-19 vaccination and the omicron variant","volume":"16","author":"Mart\u00ednez-L\u00f3pez","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10332","key":"10.1016\/j.clml.2025.11.009_bib0006","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0007","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","article-title":"Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas","volume":"192","author":"Christensen","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2025.11.009_bib0008","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijid.2023.02.011","article-title":"Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 omicron variant in the upper respiratory tract: a systematic review and meta-analysis","volume":"129","author":"Wu","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clml.2025.11.009_bib0009","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/dkae482","article-title":"Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review","volume":"80","author":"Hirsch","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"41","key":"10.1016\/j.clml.2025.11.009_bib0010","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.3346\/jkms.2024.39.e263","article-title":"Long-term outcomes of COVID-19 and risk factors for prolonged or persistent COVID-19 in lymphoma patients: a multicenter, retrospective cohort study","volume":"39","author":"Lee","year":"2024","journal-title":"J Korean Med Sci"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40472-022-00385-y","article-title":"Immunocompromised patients with protracted COVID-19: a review of \"long persisters\"","volume":"9","author":"Dioverti","year":"2022","journal-title":"Curr Transplant Rep"},{"issue":"8","key":"10.1016\/j.clml.2025.11.009_bib0012","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cmi.2024.04.009","article-title":"Persistent COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management","volume":"30","author":"Meijer","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.clml.2025.11.009_bib0013","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","volume":"24","author":"Machkovech","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clml.2025.11.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107046","article-title":"Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study","volume":"144","author":"Gr\u00f6ning","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.clml.2025.11.009_bib0016","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13756-022-01067-1","article-title":"Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values","volume":"11","author":"Thornton","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.clml.2025.11.009_bib0019","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2021.280407","article-title":"Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19","volume":"107","author":"Garcia-Vidal","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2025.11.009_bib0020","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/j.clml.2021.07.004","article-title":"Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding Rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections","volume":"21","author":"Yasuda","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QCO.0000000000001070","article-title":"Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients","volume":"37","author":"Sepulcri","year":"2024","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000523872","article-title":"COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response","volume":"145","author":"Gur","year":"2022","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10238-024-01381-5","article-title":"Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights","volume":"24","author":"Ng","year":"2024","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.clml.2025.11.009_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/23744235.2024.2446286","article-title":"Predicting persistent SARS-CoV-2 shedding in immunocompromised patients: a probability-based approach","volume":"57","author":"Chang","year":"2025","journal-title":"Infect Dis (Lond)"},{"issue":"10","key":"10.1016\/j.clml.2025.11.009_bib0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.clml.2025.11.009_bib0026","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2022.05.013","article-title":"Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses","volume":"40","author":"Lyudovyk","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0027","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.18690","article-title":"Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders","volume":"201","author":"Mikulska","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0028","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jac\/dkad105","article-title":"Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals","volume":"78","author":"Aiello","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-023-00897-5","article-title":"Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease","volume":"13","author":"Ikeda","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8001","key":"10.1016\/j.clml.2025.11.009_bib0030","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41586-024-07029-4","article-title":"Prevalence of persistent SARS-CoV-2 in a large community surveillance study","volume":"626","author":"Ghafari","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clml.2025.11.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108053","article-title":"Risk factors for persisting SARS-CoV-2 infection in patients with B-cell malignancies in the Omicron era: a multicenter cohort study","volume":"160","author":"Pasquini","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.clml.2025.11.009_bib0032","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjh.18895","article-title":"Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: a multicentre prospective cohort","volume":"202","author":"Minoia","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.11.009_bib0033","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3324\/haematol.2021.280163","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis","volume":"107","author":"Gagelmann","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.11.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109046","article-title":"A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies","volume":"110","author":"Noori","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clml.2025.11.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102040","article-title":"Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study","volume":"61","author":"Hofsink","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0036","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10096-020-03913-9","article-title":"Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards","volume":"39","author":"La Scola","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0037","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1093\/cid\/ciaa1616","article-title":"Repeated coronavirus disease 2019 molecular testing: correlation of severe acute respiratory syndrome coronavirus 2 culture with molecular assays and cycle thresholds","volume":"73","author":"Gniazdowski","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0038","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1017\/ice.2020.1273","article-title":"Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature","volume":"42","author":"Fontana","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0039","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/ciad535","article-title":"Timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19: a prospective observational cohort study","volume":"78","author":"Dzieciolowska","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jiac.2023.10.022","article-title":"Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects","volume":"30","author":"Meijer","year":"2024","journal-title":"J Infect Chemother"},{"issue":"2","key":"10.1016\/j.clml.2025.11.009_bib0041","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.clml.2025.11.009_bib0042","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/antibiotics12091460","article-title":"Sequential or combination treatments as rescue therapies in immunocompromised patients with persistent SARS-CoV-2 infection in the omicron era: a case series","volume":"12","author":"Longo","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0043","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jmii.2023.09.004","article-title":"Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir\/ritonavir and tixegavimab\/cilgavimab","volume":"57","author":"Brosh-Nissimov","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.clml.2025.11.009_bib0044","article-title":"Nirmatrelvir\/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study","volume":"11","author":"Rajme-L\u00f3pez","year":"2024","journal-title":"Ther Adv Infect Dis"},{"issue":"9","key":"10.1016\/j.clml.2025.11.009_bib0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cmi.2024.05.011","article-title":"Re: persistent COVID-19 in immunocompromised patients-Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al","volume":"30","author":"Maraolo","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.clml.2025.11.009_bib0046","doi-asserted-by":"crossref","first-page":"ofae449","DOI":"10.1093\/ofid\/ofae449","article-title":"Outcomes of antiviral retreatment for immunocompromised hosts with prolonged severe acute respiratory syndrome coronavirus 2 polymerase chain reaction positivity: a multicenter Australian Retrospective Case Series","volume":"11","author":"Bond","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0047","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12985-023-02269-8","article-title":"Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir\/ritonavir and sotrovimab","volume":"20","author":"Gentile","year":"2023","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0048","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth","year":"2024","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106413","article-title":"Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages","volume":"26","author":"Touret","year":"2023","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0050","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0051","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2025.11.009_bib0052","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/vaccines11101533","article-title":"In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 omicron lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1","volume":"11","author":"Pochtovyi","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0053","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkad027","article-title":"Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo","volume":"78","author":"Kuroda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clml.2025.11.009_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"issue":"15","key":"10.1016\/j.clml.2025.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.11.009_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0057","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.clml.2025.11.009_bib0058","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/jac\/dkad144","article-title":"High-titer convalescent plasma plus nirmatrelvir\/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients","volume":"78","author":"Huygens","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0059","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/trf.17737","article-title":"Charting a path forward: promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19","volume":"64","author":"Inbar","year":"2024","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.clml.2025.11.009_bib0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/cid\/ciad368","article-title":"Commercial immunoglobulin products contain neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 spike protein","volume":"77","author":"Upasani","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0061","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","article-title":"A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir","volume":"63","author":"Gerhart","year":"2024","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1016\/j.clml.2025.11.009_bib0062","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT)","volume":"77","author":"Lemaitre","year":"2022","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.clml.2025.11.009_bib0063","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2025.11.009_bib0064","unstructured":"University of Liverpool. COVID-19 Drug Interactions Checker. 2025. https:\/\/www.covid19-druginteractions.org\/checker. (Accessed May 25, 2025)."},{"issue":"2","key":"10.1016\/j.clml.2025.11.009_bib0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/1120009X.2024.2367935","article-title":"Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19","volume":"37","author":"Antonello","year":"2024","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0066","doi-asserted-by":"crossref","first-page":"ofad189","DOI":"10.1093\/ofid\/ofad189","article-title":"Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case Series","volume":"10","author":"Breeden","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2025.11.009_bib0067","doi-asserted-by":"crossref","first-page":"ofad612","DOI":"10.1093\/ofid\/ofad612","article-title":"A multinational case series describing successful treatment of persistent severe acute respiratory syndrome coronavirus 2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir\/ritonavir","volume":"11","author":"Snell","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2025.11.009_bib0068","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clml.2025.11.009_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.clml.2025.11.009_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109049","article-title":"Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens","volume":"27","author":"Ullah","year":"2024","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0071","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166485","article-title":"Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques","volume":"8","author":"Rosenke","year":"2023","journal-title":"JCI Insight"},{"issue":"7904","key":"10.1016\/j.clml.2025.11.009_bib0072","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.clml.2025.11.009_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072202","article-title":"Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clml.2025.11.009_bib0074","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hon.3206","article-title":"Dual combined antiviral treatment with remdesivir and nirmatrelvir\/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection","volume":"41","author":"Pasquini","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.11.009_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287300","article-title":"Case report: ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases","volume":"15","author":"Furuya","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2025.11.009_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2023.e01890","article-title":"Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma","volume":"34","author":"Jung","year":"2023","journal-title":"IDCases"},{"issue":"2","key":"10.1016\/j.clml.2025.11.009_bib0077","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jiac.2023.09.008","article-title":"Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies","volume":"30","author":"Sakamaki","year":"2024","journal-title":"J Infect Chemother"},{"issue":"11","key":"10.1016\/j.clml.2025.11.009_bib0078","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/cid\/ciad066","article-title":"Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019","volume":"76","author":"Bloch","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"20","key":"10.1016\/j.clml.2025.11.009_bib0079","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.11.009_bib0080","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.34988","article-title":"Treatment of chronic COVID-19 with convalescent\/postvaccination plasma in patients with hematologic malignancies","volume":"155","author":"Janssen","year":"2024","journal-title":"Int J Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:41:18Z","timestamp":1780990878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042958"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent COVID-19 in Patients With Hematological Malignancies: A Focused Review in the Omicron Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}